1. Articles from Avinger Inc.

    1-8 of 8
    1. Avinger Announces Primary Investigators for Upcoming VISION Trial

      Avinger Announces Primary Investigators for Upcoming VISION Trial

      Avinger Press Release - Avinger, Inc., designer of therapeutic devices incorporating intravascular imaging, and pioneer of the lumivascular approach to treating vascular disease, announces the designation of the primary investigators for its upcoming global VISION pivotal study evaluating Pantheris. Avinger is proud to announce that the primary co-investigators will be James Bennett, MD (Interventional Cardiologist), William Crowder, MD (Interventional Cardiologist) and Huey B. McDaniel, MD (Vascular Surgeon), all of Mississippi Heart and Vascular Institute at St. Dominic’s in Jackson, Mississippi and Arne Schwindt, MD (Vascular Surgeon) of St. Franziskus Hospital in Muenster, Germany. The VISION trial is a multi-center, non-randomized ...

      Read Full Article
    2. Avinger Receives FDA Clearance for Ocelot | PIXL

      Avinger Receives FDA Clearance for Ocelot | PIXL

      Avinger Press Release - Avinger Inc., a medical device manufacturer of innovative, multi-functional imaging catheters for crossing chronic total occlusions (CTOs) in patients with Peripheral Artery Disease (PAD), has received FDA clearance to market Ocelot | PIXL in the United States. Just one month after receiving clearance to commercially sell the Ocelot System in the US, the first-ever CTO crossing device with onboard imaging, Avinger debuts its newest member of the Ocelot family. “With its smaller profile and longer length, Ocelot | PIXL is designed to bring all the benefits of Ocelot to help physicians treat more patients with smaller arteries” “With its ...

      Read Full Article
    3. Avinger’s Ocelot System is FDA Cleared

      Avinger’s Ocelot System is FDA Cleared

      Avinger Press Release - Patients fighting PAD share their stories; offer new hope for an unrecognized epidemic affecting millions Avinger, Inc., a medical device manufacturer of innovative, multi-functional catheters for crossing chronic total occlusions (CTOs) in patients with Peripheral Artery Disease (PAD), announces its Ocelot System has been cleared for sale in the U.S. by the Food and Drug Administration (FDA). “It has taken my entire career to get to this moment,” said John B. Simpson PhD, MD, Avinger Founder and CEO. “Incorporating intravascular OCT into therapeutic devices has been the biggest priority here at Avinger. We have amazing investors ...

      Read Full Article
    4. Avinger To Reveal CONNECT II Clinical Trial Results for First-Ever Imaging CTO Catheter To Help Save PAD Patients’ Legs

      Avinger To Reveal CONNECT II Clinical Trial Results for First-Ever Imaging CTO Catheter To Help Save PAD Patients’ Legs

      Avinger Press Release - Avinger, Inc., a medical device manufacturer of innovative, multi-functional catheters for treating patients with Peripheral Artery Disease (PAD), announces it will reveal its CONNECT II global clinical trial results at the Vascular Interventional Advances (VIVA) Conference 2012 in Las Vegas, Nevada, October 9-12, 2012. CONNECT II is a global clinical study that evaluated the safety and efficacy of Ocelot , the first-ever interventional Chronic Total Occlusion (CTO) crossing catheter to incorporate Optical Coherence Tomography, or OCT. This technology is used to image inside the artery, allowing physicians to navigate, see, and cross totally blocked arteries in the legs ...

      Read Full Article
    5. Avinger Completes Enrollment of PAD-Focused CONNECT II Global Clinical Trial

      Avinger Completes Enrollment of PAD-Focused CONNECT II Global Clinical Trial

      Avinger Press Release - Avinger, Inc., a medical device manufacturer of innovative, multi-functional catheters for treating patients with peripheral artery disease (PAD), announced that it has successfully completed enrollment in its CONNECT II global clinical trial. PAD is a silent epidemic that affects 8 to 12 million adults in the U.S., 30 million globally and is the leading cause of amputation in patients over 50. A study published in the January 2012 American Heart Association journal Circulation claims that PAD is an unsung “pandemic” that afflicts even more women than men. “This is a major advance for patients suffering from ...

      Read Full Article
    6. FOX 16 (Little Rock, AR): Medical Breakthrough Tested in Arkansas (Incredible Hyberbole)

      FOX 16 (Little Rock, AR): Medical Breakthrough Tested in Arkansas (Incredible Hyberbole)

      The biggest medical advance since the x-ray?  Incredible hyperbole.

      LITTLE ROCK, AR - It's no bigger than a strand of hair, but it's changing the way cardiologists at the Arkansas Heart Hospital operate. "It's like working with your eyes open as opposed to working with your eyes closed," said Dr. Ian Cawich, one of the first cardiologists in the U.S. to use the device. For the first time in the country, doctors at the Arkansas Heart Hospital are operating with the Ocelot - the first ever catheter with a camera on the end allowing doctors to see inside ...

      Read Full Article
    7. Avinger Raises $22.5 Million in Series C Financing

      Avinger Raises $22.5 Million in Series C Financing
      Avinger, Inc., a medical device manufacturer of innovative, multi-functional catheters for treating patients with Peripheral Artery Disease (PAD), announces today the closing of a $22.5 million Series C funding round. All existing major investors participated in the round, with new investors contributing approximately $6 million.   “This round is expected to provide sufficient capital to further US and EU commercialization of Avinger’s Wildcat, Kittycat and Ocelot catheters,” said Kenneth Novack, Chairman of Avinger’s Board of Directors. “It will allow Avinger to continue on the path of developing the most advanced technologies to ease the suffering of people around ...
      Read Full Article
    8. Avinger Receives CE Mark Approval for Its Ocelot Catheter That Incorporates Real-Time Intravascular Guidance Using Optical Coherence Tomography (OCT)

      Avinger Receives CE Mark Approval for Its Ocelot Catheter That Incorporates Real-Time Intravascular Guidance Using Optical Coherence Tomography (OCT)
      Avinger Press Release - Avinger, Inc. announced today that it has received CE Mark approval for Ocelot – a system that combines the use of Avinger’s proprietary peripheral catheter designs incorporated with real-time Optical Coherence Tomography (OCT) for the treatment of Peripheral Artery Disease (PAD).   Ocelot is a groundbreaking new tool for accessing discrete regions of the peripheral vasculature while simultaneously providing OCT visualization for navigation through arteries. Using Ocelot’s Lightbox console as an adjunct to fluoroscopy, for the first time ever, medical professionals will have access to a therapeutic device that incorporates real time intravascular guidance.   “Ocelot CE Mark ...
      Read Full Article
    1-8 of 8
  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Doppler, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. Topics in the News

    1. (8 articles) John B. Simpson
    2. (8 articles) Avinger
    3. (3 articles) FDA
    4. (3 articles) Arne Schwindt
    5. (2 articles) St. Jude Medical
    6. (2 articles) Lightlab C7 XR OCT Imaging System
    7. (1 articles) Kenneth M. Novack
    8. (1 articles) National Institutes of Health
    9. (1 articles) UC Irvine
    10. (1 articles) National University of Ireland, Galway
    11. (1 articles) Technical University of Munich
    12. (1 articles) Roshan Dsouza
    13. (1 articles) Azhar Zam
    14. (1 articles) Martin J. Leahy
    15. (1 articles) Zhongping Chen
  3. Popular Articles

  4. Picture Gallery

    Avinger Receives CE Mark Approval for Its Ocelot Catheter That Incorporates Real-Time Intravascular Guidance Using Optical Coherence Tomography (OCT) Avinger Raises $22.5 Million in Series C Financing FOX 16 (Little Rock, AR): Medical Breakthrough Tested in Arkansas (Incredible Hyberbole) Avinger Completes Enrollment of PAD-Focused CONNECT II Global Clinical Trial Avinger To Reveal CONNECT II Clinical Trial Results for First-Ever Imaging CTO Catheter To Help Save PAD Patients’ Legs Avinger’s Ocelot System is FDA Cleared Avinger Receives FDA Clearance for Ocelot | PIXL Avinger Announces Primary Investigators for Upcoming VISION Trial